Platinum-based chemotherapy for variant castrate-resistant prostate cancer (Q36977870)

17 August 2017

Platinum-based chemotherapy for variant castrate-resistant prostate cancer (English)

1 reference

17 August 2017

1 reference

1 reference

1 reference

14

Wadih Arap

1 reference

17 August 2017

Ana M Aparicio

1

1 reference

17 August 2017

Andrea L Harzstark

2

1 reference

17 August 2017

Paul G Corn

3

1 reference

17 August 2017

Sijin Wen

4

1 reference

17 August 2017

John C Araujo

5

1 reference

17 August 2017

Shi-Ming Tu

6

1 reference

17 August 2017

Lance C Pagliaro

7

1 reference

17 August 2017

Jeri Kim

8

1 reference

17 August 2017

Randall E Millikan

9

1 reference

17 August 2017

Charles Ryan

10

1 reference

17 August 2017

Nizar M Tannir

11

1 reference

17 August 2017

Amado J Zurita

12

1 reference

17 August 2017

Paul Mathew

13

1 reference

17 August 2017

Patricia Troncoso

15

1 reference

17 August 2017

Peter F Thall

16

1 reference

17 August 2017

Christopher J Logothetis

17

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 May 2013

1 reference

17 August 2017

Clinical Cancer Research

1 reference

17 August 2017

19

1 reference

17 August 2017

13

1 reference

17 August 2017

3621-3630

1 reference

Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Modeling a lethal prostate cancer variant with small-cell carcinoma features

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Biochemical markers in prostatic cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Chemotherapy for Small Cell Carcinoma of Prostatic Origin

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Surgical management of lymph-node-positive prostate cancer: improves symptomatic control

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Carboplatin in advanced hormone refractory prostatic cancer patients.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699964

Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial

4 December 2018

1 reference

12 December 2020

Progression of prostate cancer to neuroendocrine cell tumor

1 reference

12 December 2020

Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy

1 reference

12 December 2020

Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression

1 reference

12 December 2020

Hypercalcemia in prostatic carcinoma. Report of eight cases

1 reference

12 December 2020

Small-cell carcinoma of prostate. Transient complete remission with chemotherapy

1 reference

12 December 2020

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

1 reference

12 December 2020

Small Cell Anaplastic Carcinoma of the Prostate: A Clinical, Pathological and Immunohistological Study of 27 Patients

1 reference

12 December 2020

Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent

1 reference

12 December 2020

Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis

1 reference

12 December 2020

Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers

1 reference

12 December 2020

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01

1 reference

12 December 2020

10.1158/1078-0432.CCR-12-3791

Identifiers

DOI

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

23649003

1 reference